ctDNA to Guide Breast Cancer Therapies

ctDNA to Guide Breast Cancer Therapies

by Dr. Ben Park

Life & Natural Systems Medicine & Health MJCDiseases and disordersMJCLOncology
🎙 Dr. Ben Park 👥 991 📅 December 5, 2025 ⏱ 20 min 👁 52 📄 expert opinion 🧭 2026-08-13
Available in: English (current) Français

Keywords

ctDNAliquid biopsybreast cancerneoadjuvant therapyprecision oncology

Summary

Dr. Ben Park, director of the Vanderbilt-Ingram Cancer Center, presents a case conference on the use of circulating tumor DNA (ctDNA) to guide breast cancer therapies. He begins by explaining the rationale for adjuvant therapy in early-stage breast cancer, noting that while chemotherapy improves outcomes, it leads to overtreatment and undertreatment. He introduces liquid biopsies as a potential tool to measure microscopic residual disease. He describes the concept of ctDNA, its short half-life, and the technical challenges of detecting it. He reviews his early proof-of-principle study in early-stage breast cancer and then focuses on the PREDICT DNA study in neoadjuvant setting for HER2-positive and triple-negative breast cancer. The study aimed to determine if ctDNA clearance predicts pathologic complete response (pCR) and long-term outcomes. Although the primary endpoint was not met due to a high false-negative rate for pCR, ctDNA status was a strong independent prognostic factor, outperforming pCR. He also discusses post-surgical ctDNA, where positive results are associated with high recurrence risk. He highlights the clinical dilemma of using these tests in practice, including false negatives, anxiety, and financial toxicity. He shares a case where ctDNA-guided therapy led to clearance of ctDNA, potentially offering a second chance at cure. He concludes that while trials are ongoing, these tests are already being used, and clinicians must help interpret results.

218 words

Critical Evaluation

Value of the Information & Strength of the Argument

The value of the information is high, as it provides insights from a leading expert on the clinical application of ctDNA in breast cancer. The argumentation is solid, based on data from a large prospective study (PREDICT DNA) and clinical experience. The speaker acknowledges limitations, such as false negatives and the lack of prospective evidence for clinical utility, and presents a balanced view. The case example illustrates potential benefit but is anecdotal.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is good, with references to peer-reviewed studies and the speaker’s own research. The sources are not explicitly cited in the video, but the speaker mentions the PREDICT DNA study and the use of the Personalis test. The title accurately reflects the content. The speaker discloses financial relationships, which is transparent. The video is an expert opinion, not a systematic review, but it is grounded in research.

156 words

Title / Content Match

The title accurately reflects the content, which focuses on the use of circulating tumor DNA (ctDNA) to guide breast cancer therapies.

Quality & Reliability

8/10

The presentation is given by a renowned expert in the field, Dr. Ben Park, who is the director of the Vanderbilt-Ingram Cancer Center. He presents data from his own research, including a large neoadjuvant study (PREDICT DNA) and discusses clinical experience. The information is based on peer-reviewed studies and clinical practice, but the talk is an expert opinion and includes personal anecdotes. The speaker discloses financial relationships, and the content is consistent with current scientific knowledge.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

  • Inherited Cancer Registry on Bluesky — Social media profile of the ICARE registry, mentioned in the video description.
  • Inherited Cancer Registry on LinkedIn — LinkedIn profile of the ICARE registry, mentioned in the video description.

Concurring Sources

Dissenting Sources

  • ctDNA for guiding adjuvant therapy: lack of prospective evidence — The speaker acknowledges that there is no prospective evidence yet that acting on ctDNA results improves outcomes, and some colleagues are skeptical.

Contribution & Novelties

This video provides an expert perspective on the current state and clinical application of ctDNA in breast cancer, particularly in the neoadjuvant and post-surgical settings. It highlights the PREDICT DNA study, which demonstrates that ctDNA status is a strong prognostic factor, potentially better than pCR. The speaker also discusses practical considerations for implementing ctDNA testing in clinical practice, including limitations and patient counseling.

Pour aller plus loin :

  • Circulating tumor DNA — Overview of ctDNA and its applications.
  • Liquid biopsy — General concept of liquid biopsies.
  • Neoadjuvant therapy — Explanation of neoadjuvant treatment.
  • Pathologic complete response — Definition and significance of pCR.
  • Personalis — Company providing the ctDNA test mentioned in the video.

113 words

Radar Profile

The radar profile shows high scores in quality and reliability, reflecting the expert status of the speaker and the robust data presented. The quantity of information is moderate, as the talk is a focused case conference. The technical level is high, suitable for a specialized audience.

Reliability 8/10